Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2013 Jan 17;33(4):752–759. doi: 10.1161/ATVBAHA.112.300560

Figure 2.

Figure 2

Vascular responses to 50 μmol/L BMS in cerebral arteries from SD in the presence and absence of 100 μmol/L MnTBAP, 1 mmol/L 5-HD, 5 μmol/L fluoxetine, 10 μmol/L glibenclamide, 100 nmol/L wortmannin, 10 μmol/L indomethacin, and 100 μmol/L L-NAME in endothelium-intact arteries are shown as bar graphs. In addition, vascular responses to 50 μmol/L BMS in endothelium-denuded cerebral arteries is also displayed in the bar graph. Data are mean±SEM of 4-14 experiments. (*) indicate significant difference with respect to corresponding BMS response in endothelium-intact arteries (p<0.05).

HHS Vulnerability Disclosure